1. Retrieval of vector integration sites from cell-free DNA
- Author
-
Alessio Cantore, Serena Acquati, Francesca Fumagalli, Fabrizio Benedicenti, Valeria Calbi, Marina Cavazzana, Eugenio Montini, Alessandro Aiuti, Frederic D. Bushman, Pierangela Gallina, Alessandra Magnani, Andrea Calabria, Laura Rudilosso, Maximilian Witzel, Luigi Naldini, Giulio Spinozzi, Christoph Klein, Pietro Genovese, Emmanuelle Six, Alain Fischer, Giulia Schiroli, Daniela Cesana, Cesana, D., Calabria, A., Rudilosso, L., Gallina, P., Benedicenti, F., Spinozzi, G., Schiroli, G., Magnani, A., Acquati, S., Fumagalli, F., Calbi, V., Witzel, M., Bushman, F. D., Cantore, A., Genovese, P., Klein, C., Fischer, A., Cavazzana, M., Six, E., Aiuti, A., Naldini, L., and Montini, E.
- Subjects
0301 basic medicine ,Lymphoma ,Genetic enhancement ,Genetic Vectors ,Computational biology ,Biology ,General Biochemistry, Genetics and Molecular Biology ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,law ,In vivo ,medicine ,Humans ,Liquid biopsy ,Polymerase chain reaction ,Leukemia ,Hematopoietic stem cell ,Genetic Therapy ,Leukodystrophy, Metachromatic ,General Medicine ,Genetically modified organism ,030104 developmental biology ,medicine.anatomical_structure ,Cell-free fetal DNA ,chemistry ,030220 oncology & carcinogenesis ,Cell-Free Nucleic Acids ,DNA - Abstract
Gene therapy (GT) has rapidly attracted renewed interest as a treatment for otherwise incurable diseases, with several GT products already on the market and many more entering clinical testing for selected indications. Clonal tracking techniques based on vector integration enable monitoring of the fate of engineered cells in the blood of patients receiving GT and allow assessment of the safety and efficacy of these procedures. However, owing to the limited number of cells that can be tested and the impracticality of studying cells residing in peripheral organs without performing invasive biopsies, this approach provides only a partial snapshot of the clonal repertoire and dynamics of genetically modified cells and reduces the predictive power as a safety readout. In this study, we developed liquid biopsy integration site sequencing, or LiBIS-seq, a polymerase chain reaction technique optimized to quantitatively retrieve vector integration sites from cell-free DNA released into the bloodstream by dying cells residing in several tissues. This approach enabled longitudinal monitoring of in vivo liver-directed GT and clonal tracking in patients receiving hematopoietic stem cell GT, improving our understanding of the clonal composition and turnover of genetically modified cells in solid tissues and, in contrast to conventional analyses based only on circulating blood cells, enabling earlier detection of vector-marked clones that are aberrantly expanding in peripheral tissues.
- Published
- 2021
- Full Text
- View/download PDF